相似文献
1
Rebates for anti-anemia drugs draw response from FDA, CMS.
Manag Care. 2007 Jun;16(6):17-8.
2
Erythropoietin, the FDA, and oncology.
N Engl J Med. 2007 Jun 14;356(24):2448-51. doi: 10.1056/NEJMp078100.
3
Finding a rational approach to ESA therapy--for payers and patients.
Nephrol News Issues. 2007 Sep;21(10):54, 56.
4
New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
J Support Oncol. 2007 Nov-Dec;5(10):471-3.
5
Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
Nephrol Nurs J. 2006 Nov-Dec;33(6):660-3; quiz 664-5.
6
7
Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
Nephrol News Issues. 2013 Feb;27(2):16, 18, 20.
8
FDA panel scrutinizes safety of anti-anemia drugs.
J Natl Cancer Inst. 2004 Jul 21;96(14):1061. doi: 10.1093/jnci/96.14.1061.
9
Erythropoietin claims monitoring policy: implications for clinical practice.
Nephrol Nurs J. 2006 Mar-Apr;33(2):209-13, 222; quiz 214-5.
10
ESA payment changes: chasing a moving target.
Nephrol News Issues. 2008 Jan;22(1):36-7.
Zotero 插件